AbbVie (ABBV) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $3.65
- Estimate
- $3.61
- Surprise
- +1.1%
- Score at report (before → after)
- 5.4 → 5.3/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
AbbVie (ABBV) beat the $3.61 estimate with diluted EPS of $3.65 — a modest 1.1% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.4/10) to Hold at 5.3/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ABBV Hold at 6.0/10.
3 of the last 4 quarters beat the estimate; this quarter's +1.1% surprise compares with a +1.7% four-quarter average. Next scheduled report: 2026-10-29.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.4 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Customer: McKesson, Cardinal Health, Cencora
- Concentration risk — Supplier: single-source suppliers
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $259.60
- Price target
- $299.24
- Stop
- $248.87
- Upside to target
- +15.3%
The stock trades at 74.1× trailing but 16.0× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
ABBV at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - General
- Market cap
- $459.82B
- P/E (fwd)
- 16.0
- P/E (ttm)
- 74.1
- 52-week range
- $190.75–$267.47
- Off 52-week high
- 2.9%
- RSI (14)
- 62
- Volume vs avg
- 0.67×
- Score today
- 6.0/10